Björn Nitzsche

Björn Nitzsche

Auto-generated profile, based on publicly available information

Björn Nitzsche

Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2005 in Nature
Verified
Journal Article
Closed access
PDF file
BSB. Sönnichsen
B. Sönnichsen
LKL. B. Koski
L. B. Koski
AWA. Walsh
A. Walsh
PMP. Marschall
P. Marschall
BNBeate Neumann
Beate Neumann
CEC. J. Echeverri
C. J. Echeverri

2 March 2012 in Circulation Research
Verified
Journal Article
Closed access
NTNicole A. Terpolilli
Nicole A. Terpolilli
SKSeong-Woong Kim
Seong-Woong Kim
STSerge C. Thal
Serge C. Thal
HKHiroharu Kataoka
Hiroharu Kataoka
VZVilia Zeisig
Vilia Zeisig
NPNikolaus Plesnila
Nikolaus Plesnila
Rationale:: Stroke is the third most common cause of death in industrialized countries. The main therapeutic target is the ischemic penumbra, potentially salvageable brain tissue that dies within the first few hours after blood flow cessation. Hence, strategies to keep the penumbra alive until reperfusion occurs are needed. Objective:: To study the effect of inhaled nitric oxide on cerebral vessels and cerebral perfusion under physiological conditions and in different models of cerebral ischemia. Methods and Results:: This experimental study demonstrates that inhaled nitric oxide (applied in 30% oxygen/70% air mixture) leads to the formation of nitric oxide carriers in blood that distribute throughout the body. This was ascertained by in vivo microscopy in adult mice. Although under normal conditions inhaled nitric oxide does not affect cerebral blood flow, after experimental cerebral ischemia induced by transient middle cerebral artery occlusion it selectively dilates arterioles in the ischemic penumbra, thereby increasing collateral blood flow and significantly reducing ischemic brain damage. This translates into significantly improved neurological outcome. These findings were validated in independent laboratories using two different mouse models of cerebral ischemia and in a clinically relevant large animal model of stroke. Conclusions:: Inhaled nitric oxide thus may provide a completely novel strategy to improve penumbral blood flow and neuronal survival in stroke or other ischemic conditions.

25 January 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
AHAtticus H. Hainsworth
Atticus H. Hainsworth
SAStuart Allan
Stuart Allan
JBJohannes Boltze
Johannes Boltze
CCCatriona Cunningham
Catriona Cunningham
CFChad Farris
Chad Farris
ATAron M. Troen
Aron M. Troen
Disease models are useful for prospective studies of pathology, identification of molecular and cellular mechanisms, pre-clinical testing of interventions, and validation of clinical biomarkers. Here, we review animal models relevant to vascular cognitive impairment (VCI). A synopsis of each model was initially presented by expert practitioners. Synopses were refined by the authors, and subsequently by the scientific committee of a recent conference (International Conference on Vascular Dementia 2015). Only peer-reviewed sources were cited. We included models that mimic VCI-related brain lesions (white matter hypoperfusion injury, focal ischaemia, cerebral amyloid angiopathy) or reproduce VCI risk factors (old age, hypertension, hyperhomocysteinemia, high-salt/high-fat diet) or reproduce genetic causes of VCI (CADASIL-causing Notch3 mutations). We concluded that (1) translational models may reflect a VCI-relevant pathological process, while not fully replicating a human disease spectrum; (2) rodent models of VCI are limited by paucity of white matter; and (3) further translational models, and improved cognitive testing instruments, are required.

1 April 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
ATAladdin Taha
Aladdin Taha
JBJoaquim Bobi
Joaquim Bobi
RDRuben Dammers
Ruben Dammers
RDRick M. Dijkhuizen
Rick M. Dijkhuizen
ADAntje Y. Dreyer
Antje Y. Dreyer
HBHeleen M.M. van Beusekom
Heleen M.M. van Beusekom
Translation of acute ischemic stroke research to the clinical setting remains limited over the last few decades with only one drug, recombinant tissue-type plasminogen activator, successfully completing the path from experimental study to clinical practice. To improve the selection of experimental treatments before testing in clinical studies, the use of large gyrencephalic animal models of acute ischemic stroke has been recommended. Currently, these models include, among others, dogs, swine, sheep, and nonhuman primates that closely emulate aspects of the human setting of brain ischemia and reperfusion. Species-specific characteristics, such as the cerebrovascular architecture or pathophysiology of thrombotic/ischemic processes, significantly influence the suitability of a model to address specific research questions. In this article, we review key characteristics of the main large animal models used in translational studies of acute ischemic stroke, regarding (1) anatomy and physiology of the cerebral vasculature, including brain morphology, coagulation characteristics, and immune function; (2) ischemic stroke modeling, including vessel occlusion approaches, reproducibility of infarct size, procedural complications, and functional outcome assessment; and (3) implementation aspects, including ethics, logistics, and costs. This review specifically aims to facilitate the selection of the appropriate large animal model for studies on acute ischemic stroke, based on specific research questions and large animal model characteristics.

13 August 2008 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
PDF file
JBJohannes Boltze
Johannes Boltze
AFAnnette Förschler
Annette Förschler
BNBjörn Nitzsche
Björn Nitzsche
DWDaniela Waldmin
Daniela Waldmin
AHAnke Hoffmann
Anke Hoffmann
UGUwe Gille
Uwe Gille
As effective stroke treatment by thrombolysis is bound to a narrow time window excluding most patients, numerous experimental treatment strategies have been developed to gain new options for stroke treatment. However, all approaches using neuroprotective agents that have been successfully evaluated in rodents have subsequently failed in clinical trials. Existing large animal models are of significant scientific value, but sometimes limited by ethical drawbacks and mostly do not allow for long-term observation. In this study, we are introducing a simple, but reliable stroke model using permanent middle cerebral artery occlusion in sheep. This model allows for control of ischemic lesion size and subsequent neurofunctional impact, and it is monitored by behavioral phenotyping, magnetic resonance imaging, and positron emission tomography. Neuropathologic and (immuno)-histologic investigations showed typical ischemic lesion patterns whereas commercially available antibodies against vascular, neuronal, astroglial, and microglial antigens were feasible for ovine brain specimens. Based on absent mortality in this study and uncomplicated species-appropriate housing, long-term studies can be realized with comparatively low expenditures. This model could be used as an alternative to existing large animal models, especially for longitudinal analyses of the safety and therapeutic impact of novel therapies in the field of translational stroke research.

1 February 2019 in NeuroImage
Verified
Journal Article
Closed access
BNBjörn Nitzsche
Björn Nitzsche
JBJohannes Boltze
Johannes Boltze
ELEberhard Ludewig
Eberhard Ludewig
TFThomas Flegel
Thomas Flegel
MSMartin J. Schmidt
Martin J. Schmidt
SSSabine Schulze
Sabine Schulze